The Effective Targeting of KRASG12C Elusiveness

被引：1
|
作者：
Elez, Filiation Elena [1 ]
Tabernero, Josep [1 ]
机构：
[1] Univ Autonoma Barcelona UAB, Dept Med Oncol, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
来源：
CANCER CELL | 2020年 / 38卷 / 06期
关键词：
MECHANISM; KRAS;
D O I：
10.1016/j.ccell.2020.11.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Developing therapies to directly target KRAS is challenging. In The New England Journal of Medicine, Hong et al. report a promising KRAS-targeting therapy phase I trial. However, a deeper understanding of the underlying biology of each histological context might well be required to optimize the potential benefit of this class of agents.
引用
收藏
页码：785 / 787
页数：3
相关论文
共 50 条
  • [41] Early promising results with the novel KRASG12C inhibitor divarasib
    Diana Romero
    Nature Reviews Clinical Oncology, 2023, 20 : 733 - 733
  • [42] Unlocked groove-developing covalent inhibitors of KRASG12C
    Lipford, J. Russell
    Cee, Victor
    Lanman, Brian
    Saiki, Anne
    Rex, Karen
    Volak, Laurie
    Shimanovich, Roman
    Hinkle, Beth
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 24 - 25
  • [43] The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
    Kwan, Albert K.
    Piazza, Gary A.
    Keeton, Adam B.
    Leite, Caio A.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [44] KRASG12C mutation in metastatic colorectal cancer: a new target
    Ibrahim, Rebecca
    Saleh, Khalil
    Chahine, Claude
    Khoury, Rita
    Khalife, Nadine
    Lecesne, Axel
    FUTURE ONCOLOGY, 2023, 19 (24) : 1641 - 1643
  • [45] Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
    Bekaii-Saab, Tanios S.
    Yaeger, Rona
    Spira, Alexander I.
    Pelster, Meredith S.
    Sabari, Joshua K.
    Hafez, Navid
    Barve, Minal
    Velastegui, Karen
    Yan, Xiaohong
    Shetty, Aditya
    Der-Torossian, Hirak
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4097 - +
  • [46] Preclinical efficacy of KRASG12C inhibitors in models of pediatric cancer
    Price, Hannah
    Stauffer, Stacey
    Powell, Katie
    Baker, Andrew
    Perciaccante, Andrew
    Hernandez, Edjay Ralph
    Odeniyide, Patience
    Pratilas, Christine
    Burgan, William
    Jenkins, Lisa
    Rossman, Kent L.
    Yohe, Marielle
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [47] Early promising results with the novel KRASG12C inhibitor divarasib
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (11) : 733 - 733
  • [48] KRasG12C inhibitors in clinical trials: a short historical perspective
    Goebel, Lisa
    Mueller, Matthias P.
    Goody, Roger S.
    Rauh, Daniel
    RSC MEDICINAL CHEMISTRY, 2020, 11 (07): : 760 - 770
  • [49] Drugging the undruggable: a computational chemist's view of KRASG12C
    Bodnarchuk, Michael S.
    Cassar, Doyle J.
    Kettle, Jason G.
    Robb, Graeme
    Ward, Richard A.
    RSC MEDICINAL CHEMISTRY, 2021, 12 (04): : 609 - 614
  • [50] AZD4625 is a Potent and Selective Inhibitor of KRASG12C
    Chakraborty, Atanu
    Hanson, Lyndsey
    Robinson, David
    Lewis, Hilary
    Bickerton, Sue
    Davies, Michael
    Polanski, Radoslaw
    Whiteley, Rebecca
    Koers, Alex
    Atkinson, James
    Baker, Tamara
    Barrantes, Ivan del Barco
    Ciotta, Giovanni
    Kettle, Jason G.
    Magiera, Lukasz
    Martins, Carla P.
    Peter, Alison
    Wigmore, Eleanor
    Underwood, Zoe
    Cosulich, Sabina
    Niedbala, Michael
    Ross, Sarah
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (10) : 1535 - 1546
12345